Skip to main content

Advertisement

Log in

Safety of retroviral gene marking with a truncated NGF receptor

  • Letters to the Editor
  • Published:

From Nature Medicine

View current issue Submit your manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Li, Z. et al. Murine leukemia induced by retroviral gene marking. Science 296, 497 (2002).

    Article  CAS  Google Scholar 

  2. Bordignon, C. & Bonini, C. A clinical protocol for gene transfer into peripheral blood lymphocytes for in vivo immunomodulation of donor anti-tumor immunity in patients affected by recurrent disease after allogeneic bone marrow transplantation. Hum. Gen. Ther. 2, 813–819 (1995).

    Article  Google Scholar 

  3. Bonini, C. et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science 276, 1719–1724 (1997).

    Article  CAS  Google Scholar 

  4. Rosenberg, N. & Jolicoeur, P. Retroviral pathogenesis. in Retroviruses (eds. Coffin, J.M., Hughes, S.H. & Varmus, H.) 413–416 (Cold Spring Harbor Laboratory Press, New York, 1997).

    Google Scholar 

  5. Hacein-Bey-Abina, S. et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N. Engl. J. Med. 348, 255–256 (2003).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to C. Bonini.

Ethics declarations

Competing interests

C.T., M.R., C. Benati, S.T. and C.G.-S. are present full-time employees of Molmed S.p.A., an organization that could gain or lose financially through publication of this paper. T.A. is a former employee of SyStemix, a former subsidiary of Novartis that acquired intellectual property and rights on the work performed by SyStemix, and therefore could gain or lose financially by publication of this paper. M.I. is sponsored by Molmed S.p.A. F. Mavilio is a paid consultant of Molmed S.p.A. C. Bordignon is a member of the Board of Directors of Molmed S.p.A.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bonini, C., Grez, M., Traversari, C. et al. Safety of retroviral gene marking with a truncated NGF receptor. Nat Med 9, 367–369 (2003). https://doi.org/10.1038/nm0403-367

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nm0403-367

  • Springer Nature America, Inc.

This article is cited by

Navigation